Ousia Pharma uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of our lead candidate (OP-56) within general and rare-genetic obesity.
According to WHO, more than 2 billion people throughout the world are overweight and more than 650 million are considered obese. This leaves a huge unmet need within obesity treatment and a need for revolutionary drug development. Ousia Pharma is developing anti-obesity treatments with novel mechanism of action for a potent and safe weight loss. Our lead compound carries a dual effect, extracting optimal efficacy from each component.
Our research into the neurobiology of appetite regulation, identified NMDA receptor (NMDAR) antagonism as a potent pharmacological target for the treatment of obesity. However, the therapeutic utility of NMDAR antagonists is hampered by intolerable dose-dependent adverse effects. Determined to harvest the metabolic benefits of NMDAR antagonism, we have engineered first-in-class peptide-NMDAR antagonist drug conjugates that are currently being developed for the treatment of obesity.
